CSL in battle over Haemophilia drug

AUSTRALIAN vaccines and blood products developer CSL will vigorously fight a new patent infringement claim in relation to its haemophilia B drug, Idelvion.

US-based biotechnology group Bioverativ has filed complaints in the US District Court for the District of Delaware and with the International Trade Commission.

Read more